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The role of the Public Health Service in the poliomyelitis problems 
of 1955 may be grouped into three main activities:
1. The licensing of products and producers and the clearance 
of vaccines;
2. The administration of federal grant-in-aid funds and of the 
voluntary interstate program for the distribution of vaccine;
3. The surveillance of the disease and the field evaluation 
of the safety and effectiveness of vaccines.
The present report will be limited to the surveillance activities.
The National Poliomyelitis Surveillance Program was established 
by the Surgeon General of the Public Health Service on April 28, 1955 
immediately after the recognition that cases of poliomyelitis were 
occurring in association with vaccine manufactured by Cutter Laboratories.
The purpose of the Program was to provide a clearing house for 
the collection, consolidation and dissemination of all pertinent epi­
demiologic information regarding the poliomyelitis problems confronting 
the nation.
The Poliomyelitis Surveillance Unit was established in the Communi­
cable Disease Center with headquarters in Atlanta, Georgia. Cooperative 
arrangements were made for the direct exchange of reports with all states 
and territories and with more than UO virus laboratories both in govern­
ment and in academic institutions. A total of h2 Epidemic Intelligence 
Service Officers including 29 physicians, k nurses, 6 statisticians and 
3 veterinarians were either assigned to full time polio duty or alerted 
for first priority polio investigation, as needed. Funds were made 
available for diagnostic support of surveillance activities to the 
collaborating laboratories first through the Sectional Research Program 
of the National Microbiological Institute and after July 1, 1955 through 
the Communicable Disease Center.
Poliomyelitis Surveillance Reports have been issued regularly since 
May 1 to all State Health Officers, state epidemiologists, directors of 
participating laboratories and many others having responsibilities in the 
field of poliomyelitis. News releases giving summaries of the data were 
issued from the Surgeon General's office. Much of the information collected 
by the Polio Surveillance Unit was used in the "Technical Report on Salk 
Poliomyelitis Vaccine," issued June 10, 1955> and the "Report on Polio­
myelitis Vaccine Produced by Cutter Laboratories", issued on 
August 25, 1955*
Opportunity is taken at this time to present a more complete 
account of the National Poliomyelitis Surveillance Program. This report 
will consider two main questions. The first will be an epidemiologic 
evaluation of the safety of polio vaccines as used this year including a 
documentation of the difficulties arising from the use of some vaccine 
manufactured by the Cutter and Wyeth Laboratories, and an appraisal of 
the safety of vaccines in current use. The second question will be a 
preliminary evaluation of the effectiveness of the vaccines as actually 
used this year,
The authors wish to emphasize that the data included in this paper 
were reported by the states and the participating laboratories. Their 
contribution is gratefully acknowledged.
Epidemiologic Observations on Vaccine Safety
The first concern of the Poliomyelitis Surveillance Unit was 
the prompt verification of reports to make possible an evaluation
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of the significance of the cases of poliomyelitis which were occurring 
among recently vaccinated children. Shortly, the occurrence of cases 
among family contacts of vaccinated children broadened the scope of the 
problem. The possibility of community spread from these sources also 
caused great concern, but fortunately this proved to be of relatively 
limited consequence. Thus three types of vaccine associated cases were 
recognized namely, vaccinated cases, family contact cases and community 
contact cases.
The cases of poliomyelitis associated with Cutter vaccine are shown 
in Table 1 by state of report, type of association and paralytic status.
A total of 20k associated cases with 11 deaths have been accepted by the 
Poliomyelitis Surveillance Unit. Of these, 79 were among vaccinated indi­
viduals, 105 among family contacts and 20 among community contacts. Three- 
fourths of the cases were paralytic. The case fatality rate was five per 
cent. The cases were concentrated in California and Idaho where certain 
lots of Cutter vaccine were provided by the National Foundation for 
Infantile Paralysis (NFIP) for first and second grade school children.
Cutter vaccine was also used in school clinics in Nevada, Arizona, New 
Mexico and Hawaii. The cases that occurred in small numbers in the other 
states were associated with vaccine that had been distributed in commercial 
channels.
The distribution of the vaccine provided by the NFIP is shown in 
Table 2 by lot number and state. The extent of usage of the commercial 
lots of vaccine is not shown. The incidence of vaccinated cases and total 
associated cases by lot number is shown in Table 3* A total of 67 cases 
were associated with either lot 6039 or 6058. These two lots were used 
in Idaho and for many cases a distinction between thoslots was not possible.
- it. .
Cases were associated with all but two of the other lots provided by the 
WFIP and with all but one of the lots distributed commercially.
The distribution of Cutter associated cases by interval from date 
of inoculation to date of first symptoms is shown in Table If-. The vacci­
nated cases are concentrated in the period k to li+ days whereas the family' 
contact cases are concentrated in the period 8 to 28 days which represents 
a double incubation period.
The three phases of the Cutter Incident are shown geographically in 
Figure 1. On April 27 when only six cases associated with Cutter vaccine 
had been reported it was observed that the dates of inoculation were con­
centrated in the early period after release of the vaccine, and the 
intervals from inoculation to first paralysis seemed short. These findings 
provided a basis for some epidemiologists to predict a substantial out­
break of 100, 200, or even as many as 500 cases among vaccinated children. 
Actually, only 79 cases were reported.
During the middle of May when the first cases among family contacts 
came to recognition, similar short intervals were also noted and the pre- 
diction was made that 100 or more cases would occur among family con­
tacts . Actually 10k cases were reported.
Wo community contact cases came to recognition for 12 days after 
the first family contact cases were reported and then only in small 
numbers. It was not possible to predict the numbers to be expected and 
only 20 were reported.
Figure 1 includes only the paralytic vaccine associated cases.
The predicted curves are based upon incubation period data reported by 
Bodian (l) from inoculation of Mahoney virus intramuscularly into 
Cynomolgus macaques, assuming an even distribution of vaccinations from 
April l6 to 27*
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One of the characteristics of the Cutter associated vaccinated 
cases was the correlation of site of first paralysis with site of 
inoculation. Similar findings have been reported by Bodian (2) in 
Cynomolgus macaques. The data are summarized in Table 5* The similarity 
of the findings is striking.
Table 6 presents a summary of the laboratory findings from Cutter 
associated cases and their contacts. Isolations of polio virus have been 
reported in association with about one-half of the paralytic cases and 
about one-third of the non"paralytic cases. Type I virus has been 
identified in association with 100 cases and Type II and Type III virus 
on single occasions. Wot included in the table is a report by Dr. John Fox 
of Tulane University of the isolation of Type III virus from a fatal 
vaccinated case from which a previous isolation of Type I virus had also 
been made.
These are the epidemiological data which support the conclusion in 
the Cutter Report, "....the development of the disease in some of these 
patients was the result of the presence, in infective amounts, of live 
poliomyelitis virus in some distribution lots of Cutter vaccine."
The experience with Cutter naturally alerted all health officials 
to the possibility of other outbreaks of inoculation poliomyelitis. In May, 
a small number of cases were reported from Pennsylvania in children who had 
recently received vaccine made by Wyeth Laboratories. Three cases had 
developed initial paralysis in the inoculated extremity. A special study 
was immediately undertaken. Additional cases were discovered in family 
and community contacts and also in a number of persons without history of 
vaccination or contact. This evidence was insufficient to exclude the 
possibility that the reported associations were coincidental.
Later, however, several cases associated with one lot of Wyeth
- 6 -
vaccine was reported from Maryland. These occurred not only among 
vaccinated children hut also among family and community contacts under 
circumstances that raise strong suspicion of some explanation other than 
coincidence.
This lot of vaccine has been tested extensively in both tissue 
culture and monkey tests by the Division of Biologic Standards of the 
National Institutes of Health and independently by collaborating labora­
tories . No poliomyelitis viruses have been isolated.
Both of the foregoing occurrences involved lots of vaccine that were 
released and used shortly after the announcement of the results of the 
195^ Field Trials. On May 7> the Surgeon General recommended temporary 
suspension of the vaccination program pending a full reappraisal of the 
safety testing and clearance procedures for vaccines. By that time over 
four million inoculations had been given. Except for the incidence of 
poliomyelitis in connection with certain lots of Cutter and one lot of Wyeth 
vaccine, no other situation involving the possibility of unsafe lots of 
vaccine was recognized.
Beginning on May 13, and continuing to-the present, all lots of 
vaccine have been released under revised safety standards. Epidemiologic 
surveillance for possible untoward incidents has been constantly main­
tained. All states and territories have been and are reportlrgcases of 
poliomyelitis which occur among vaccinated children. These are tabulated 
by lot number so that individual cases associated with the same lot but 
occurring in separate states will be promptly recognized. Special 
attention is directed toward cases which occur at an interval of k to lU 
days after inoculation and to paralytic cases showing first paralysis at 
the site of inoculation. The essential data on each case occurring in a 
vaccinated person are printed in the Surveillance Report^ thus making these 
data available to all responsible authorities.
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The cases of poliomyelitis that have been reported among vaccinated 
persons since the first of July have shown certain distinctive characteris­
tics. Over three-fourths have been reported as non-paralytic. Most have 
occurred more than 30 days after vaccination, and only a few in the interval 
4 to Ik days. Among the relatively infrequent paralytic cases, instances 
with first paralysis occurring at the site of inoculation have been con­
spicuously rare. No single lot of vaccine has been associated with more 
than one such case. Thus no evidence has come to light that tends to 
incriminate any lot of vaccine of any manufacturer that has been released 
and used since the new safety standards were adopted.
Evaluation of Effectiveness
Special Studies: During the period prior to May 7 , when inoculations
were temporarily suspended, few plans had been made to conduct controlled 
studies of the effectiveness of the vaccines in current use. The antici­
pated flow of fairly large supplies of vaccine and the known great demand 
for it seemed to preclude the possibility of selecting adequate control 
groups. When it became apparent, however, that supplies of vaccine would 
not be sufficient even to meet the commitments of the NFIP contracts a 
unique opportunity for evaluation studies was presented. The situation 
had similarities to the observed control studies of the 195^ Field Trials 
except that approximately ten times as many school children had received 
at least one inoculation, and prior arrangements for evaluation had not 
been made.
Many states rapidly developed plans for special studies in 
collaboration with C1JC. Epidemic Intelligence Service officers were
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assigned to participate in many areas. Funds that were being made avail­
able to the participating laboratories were directed to the support of 
these studies. The gathering together of data regarding effectiveness 
of the vaccine as-used in 1955 became a major aspect of the Surveillance 
Program. Special studies of varying degree of detail are in progress in 
approximately 20 states. In some of these, the groups inoculated during 
the 1954 Field Trials remain under observation and are large enough to 
give promise of some evaluation of the duration of immunity and the 
effectiveness of booster inoculations. Preliminary reports have been 
received from 11 states and one city for inclusion in this paper.
The preliminary report from New York State, submitted by Dr. William 
G. Beadenkopf, illustrates the basically simple pattern of these special 
studies (Table 7)• Four distinct groups of immunized children, totalling 
almost 1+50,000, are under observation, along with a group of 282,000 
unvaccinated children. Attack rates for paralytic cases are *+.0 per 
100,000 for the total inoculated group and 20.9 for the uninoculated 
children making a ratio of greater than 5 to 1 in favor of the vaccine. 
Attack rates for non-paralytic cases are 28.5 among vaccinated children 
and 39.lt- among the unvaccinated, the ratio of these two rates being some­
what less than 3 to 2 in favor of the vaccine. Distinctions in attack 
rates for either paralytic or non-paralytic cases among the four separate 
groups of vaccinated children are not evident. The absence of paralytic 
cases from the small group of children inoculated in 195*+ and boosted in 
1955 is interesting but not statistically significant. When final data 
are available giving more accurate classification of paralytic cases and
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laboratory confirmation or exclusion of the cases now classified as non­
paralytic , considerable differences in the rates may be anticipated, 
although it seems doubtful that the 5 to 1 differences in incidence of 
paralytic cases among vaccinated children will be nullified,
Table 8 presents a simple summaiy of preliminary reports of special 
studies that have been submitted from 11 states and New York City, The 
size of the study populations and the number of cases by paralytic status 
are shown for each state. These data were used to calculate attack rates 
as shown in Table 9, There is a marked difference between the attack 
rates for the vaccinated and unvaccinated groups. For paralytic cases, 
the rates are from two to more than five times greater in the un­
vaccinated than in the vaccinated groups. For the non-paralytic cases, 
no differences were observed in some states and rates up to two or more 
times greater in others.
In evaluating these preliminary reports many possible sources of 
error must be kept in mind such as the accuracy and completeness of the 
history of vaccination, the criteria for classification of paralytic 
status, and the accuracy of the population estimates. In some areas 
outbreaks of diseases that clinically resemble non-paralytic polio have 
been prevalent, another problem arises in classifying cases of polio 
developing shortly after inoculation and before immunity can be expected 
to have developed. These and other factors of bias must be considered, 
When final reports are available many differences from these preliminary 
figures may be expected. At present it is difficult to judge whether 
these factors of bias serve to exaggerate or minimize the effect of the 
vaccine.
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Because of these unassessed factors of bias a search was made for 
some independent confinnation of the results of these special studies.
The Age Distribution Analysis Study was designed for this purpose. Since 
it was known that the age-specific attack rates for poliomyelitis followed 
a relatively continuous distribution curve and since use of poliomyelitis 
vaccine had been restricted almost solely to 1st and 2nd grade children 
representing mostly 7 and 8 year olds, a discontinuity should appear 
in the age distribution this year if the vaccine were effective.
In collaboration with 33 states, data on age,- onset and reported 
paralytic status of all cases of poliomyelitis are being submitted to the 
Polio Surveillance Unit, As a control similar tabulations for the year 
1952 have been compiled from 21.of these 33 states. Figure 2 shows the 
geographic distribution of the states participating in this aspect of the 
Surveillance Program,
The upper hald of Figure 3 shows curves describing paralytic polio­
myelitis for 1952 and 1955, drawn from data presented in Table 10, The 
absolute level of the rates for the two years differs because of the 
severity of the epidemic in 1952 compared to 1955 and because data for the 
full calendar year are included for 1952 and data only for the period 
July 3 through October lU are included for 1955. The two curves have been 
superimposed by a simple arithmetic transposition. The two rate scales 
are clearly shown.
The two distribution curves for paralytic cases are similar with 
one major exception, namely a relatively sharp lowering of the rates for 
ages 7 and 8 in 1955, This discontinuity in the age distribution curve 
is limited to the ages in which poliomyelitis vaccine was widely used this 
year. This discontinuity constitutes independent evidence of the
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effectiveness of the vaccine against paralytic polio.
In the lower half of Figure 3 are shown the age distribution curves 
for non—paralytic cases in 1952 and 1955, A different transposition factor 
has been used to superimpose the curves. No sharp discontinuity is dis­
cerned that can be clearly attributed to an effect of the vaccine.
Summary
The National Poliomyelitis Surveillance Program was initiated in 
April 1955 to serve as a clearing house for the collection, consolidation, 
and dissemination of all pertinent epidemiologic information concerning 
the poliomyelitis problems facing the nation. Headquarters of the Program 
are located in the Communicable Disease Center in Atlanta, Georgia, All 
states and territories are collaborating in the Program, More than i|0 
laboratories are participating. Epidemic Intelligence Service Officers 
have served with first priority duty throughout the spring and summer and 
many are still working essentially full time on poliomyelitis.
The Surveillance Program has been concerned with two main problems, 
1) the epidemiologic evaluation of the safety, and 2) the measurement of 
the effectiveness of the vaccine,
A total of 20U cases of poliomyelitis with 11 deaths are known to 
have occurred in association with vaccine manufactured by Cutter Labora­
tories, Of these, 79 were among vaccinated children, 105 among family 
contacts of vaccinated children and 20 among community contacts. The 
epidemiologic pattern of these cases, including 1) their geographic 
distribution, 2) the association of cases with particular lots of vaccine, 
3) the grouping of the onsets of most of the cases with appropriate
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incubation periods following inoculation, and U) the correlation between 
the site of inoculation and the site of first paralysis in a majority of 
the vaccinated cases, supports the conclusion that live virus in infective 
amounts was present in some distribution lots of Cutter vaccine,
1 A problem was also encountered in the epidemiologic evaluation 
of a few cases of poliomyelitis that occurred in association with one 
lot of vaccine manufactured by Wyeth Laboratories, Except for the 
difficulties with some lots of Cutter and one lot of Wyeth vaccine, how­
ever, no other situation involving the possibility of unsafe lots of vaccine 
was recognized in the more than four million inoculations that were given 
in April and early May.
Since the middle of May, when a complete revision of safety stand­
ards and clearance procedures was adopted, no epidemiologic evidence has 
come to light that tends to render suspect any lot of vaccine of any 
manufacturer.
Preliminary reports indicate encouraging results regarding the 
effectiveness,of the vaccine. The restriction of inoculations to 1st 
and 2nd grade school children during the spring and summer of 1955 pro­
vided a unique opportunity for special studies to evaluate effectiveness. 
Approximately 20 states are conducting such investigations. Tentative 
results, subject to modification and revision, reveal that the attack 
rates for paralytic polio are from two to more than five times greater 
in the unvaccinated than in the vaccinated children. Less marked but 
favorable differences are reported for non-paralytic cases.
Confirmation of these preliminary findings has been obtained from 
a study of the pattern of the age distribution of cases of polionyelitis 
reported this year from 33 states, A sharp reduction in paralytic attack 
rates in 7 and 8-year-old children has been observed, in comparison to
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the expected rates based on past experience. This finding constitutes an 
independent confirmation of the effectiveness of the vaccine as used 
this year*
— i l l  .«• ■
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Table 1
Poliomyelitis Cases and Deaths Associated with Cutter Vaccine 
by State and Paralytic Status
Vaccinated Family Con- Community.',Con- Total asso- 
State Cases tact Cases tact Cases dated Cases Total
? HP Total P HP Total P NP Total P Nr Total Deaths
Alabama 1 1* 1 1 1
Arizona 1 . 1 2 3 3 1 k 5
California 27 11 38 28 10 38 2 1 3* 57 22 79 1
Colorado 1 1 2 2 3 3
Connecticut 1 1 • . 1 1
Georgia 1 1 3 3* 1+ 4 1
T. Hawaii 1 1* 2 2 3 3 1
Idaho 17 3 20** 28 8 36* b 1 5 k9 12 61 4
Illinois l 1 1 1
Louisiana l 1* 1 1 2 2 1
Maryland 1 1 b 1 5 5 1 6
Minnesota 1 l 1 l
Missouri l 1 1 l
Montana 1 1* 1 1 .1
Nevada 3 l k b 1 5 7 2 9
New Mexico 2 1 3 2 1 3
New York l 1 1 l
Ohio l 1 1 1* 2 2 1
Oregon 3 3 3 1 1 1 7 1 8
Tennessee l 1 1 1
Texas l l 1 2 2
Virginia 1 l 1 1
'Washington l l 2 1 3 3 3 6 1 7
Wyoming l l 1 1
Total
Cases 6l IS 79 80 25 105 17 3 20 158 kb 204 11
Percent m zy]o 775-
Paralytic
Total
Deaths 5 k 2 11
Case Fatality
Bate ' l i 1 1 t 10$ 5$
* Including one fatal case.
** Including three fatal cases.
Notes on back.
Notes to Table 1
Table 1 includes all cases associated with Cutter vaccine which 
have been "accepted'' by the Poliomyelitis Surveillance Unit through 
October 28, 1955* "Accepted" cases meet the following criteria:
1) All cases have been classified as bona fide polio by the 
Polio Reporting Officer submitting the case.
2) Minimum essential data (county residence, age, sex, date 
of inoculation, date of onset, paralytic status and 
manufacturer of vaccine used) have been included in the 
report submitted.
It should be noted that for the purposes of this presentation 
vaccine associated cases used in the tabulations were selected in the 
following way:
1) Vaccinated Cases: all cases included had onsets before
June 1, 1955, so that no cases with onsets more than 50 days 
after inoculation are included.
2) Family Contact Cases: all cases included had onsets
before June 15, 1955> so that no cases with onsets more 
than 65 days after inoculation of the vaccinated contact 
are included.
3) Community Contact Cases: all accepted cases are included
without restriction as to date of onset. However, reporting 
of Community Contact Cases was discontinued on August 1, 1955*
These data are not final; minor additions, deletions, and 
corrections are to be expected.
Table 2
The Distribution of Cutter Vaccine by Lot Dumber and State
Commercial First Inoculations in ochool Clinics
Lot Dumber Inoculations Arizona California Hawaii Idaho Nevada Dew Mexico Total
5721 39,000 39,000
5927 * 1+3,000592S IS,000 25,000
5970 ** 21,000 21,000
5971 *
5972 *
5973 *
597* *1 *
5975 *
1+0,0005976 7,000 21,000 12,000
5977 3,000 ** 3,000
6037 11,000 20,000 32,000 63,000
603s 2,000 1+8,000 3,000 9,000 9 ,000 61,000
6039 2,000 20,000 7,000 3,000 32,000
Gobk *
601+5 *
6058 ** 12,000 12,000
Totals * 35,000 172,000 5,000 32,000 11,000 51,000 309,000
Data for this table contributed in part by the National Foundation for Infantile Paralysis from 
reports from state Health Departments, and by the Vaccine Activities Section, Bureau of State 
Services, Public Health Service.
* These lots distributed through commercial channels and 3Xact usage not known.
** Less than 500 inoculations.
Poliomyelitis Cases Associated with. Cutter Vaccine by Lot Humoer
Table 3
Humber of Vaccinated Eamily Con- Community Con- Total Asso- Total Associated Cases
Lot Humber Inoculations Cases tact Gases tact Cases dated Cases per 100,000 Inoculations
Vaccine Distributed to School Clinics
5721 3^,000 0 0 0 0 —
5928 43,000 4 1 0 5 11.6
5970 21,000 0 3 0 3 14.3
5976 40,000 2 3 0 5 12.5
5977 3,000 0 0 0 0 -—
6037 63,000 6 3 0 9 14.3
6038 6l,GOO 5 4 0 9 l4.S
6039 or 6058=* 44,000 21 4i _5. §L i5ga3.
Total 309,000 3S 55 5 98 31.7
Vaccine Distributed Through Commercial Channels
5927 ** 1 0 0 1
5971 ** 7 5 1 13 ,
5972 ** 8 9 1 18
5973 ** 1 2 3 6
597^ ** 1 0 0 l
5975 ** 0 0 0 0
6o44 sie* 4 2 6 12
6045 ** 10 _Z _2 1 1
Total ** 32 25 13 70
Cases with data incomplete 9 25 2
Total Cases -79 105 20 204
Idaho cases received cither Lot 6039 or 6058.
** Exact usage not known.
Table li
Poliomyelitis Cases Associated with Cutter Vaccine 
by Interval from Inoculation to First Symptoms
Vaccinated Family Community
Interval* Cases Contact Cases Contact Cases
(Days) P NP Total P NP Total P NP Total
0-3 3 1 h 1 1
h -7 36 3 39 1 1
8-lU 18 7 25 9 3 12
13-21 1 6 7 20 3 23 2 2
22-28 2 2 26 10 36 5 1 6
29-35 6 3 9 h 1 5
36-14.2 1 1 7 2 9 b h
h3-h9 1 1 5 1 6 1 l
Data
Incorrplete 6 2 8 2 2
Totals 61 18 79 80 25 105 17 3 20
-^Interval from inoculation of vaccinated contact to onset 
of case used for all contact cases.
Table 5
Paralytic Poliomyelitis in Cutter Vaccinated Individuals 
Compared with Experimental Data in the Cynomolgus fecaque
Interval from 
Inoculation to 
First Paralysis
Site of First Paralysis 
In Inoculated Distant from Site 
Extremity of Inoculation
Data
Incomplete
Tot,
Number
als
Percent
Monkey Data* 
Number Percent
0-3 days
U-7
8-1U
15-21
22 or more
Number
Totals
Percent
9
29
2
3
10
3
3
2
12
la
5
3
20$
67$
8$tcfP/O
3
23
5
1
9$
72$
16$
3$
Uo
66$
19
31$
2
3%
6l
100$
100$ 32 100$
Number 2 3 ^ 9(2) 32
Monkey Data*-”-
Percent 12% 28$ 100$
Data abstracted from David Bodian (Reference 1). In the experiment cited, live Mahoney virus 
was injected into the right calf of 32 Cynomolgus macaques. The animals were examined twice 
daily to determine the date and site of initial paralysis.
Personal communication from Dr. Bodian of unpublished, observations from the experiment cited above.
(1) In some cases initial paralysis developed simultaneously in several extremities, 
including the right leg.
(2) In some cases initial paralysis developed simultaneously in several sites, but in all 
cases the right leg was not involved at the time when paralysis was first noted.
Table 6
Poliomyelitis Cases Associated with Cutter Vaccine 
With One or More Virus Isolations from the Patient or Contacts
Vaccinated Family Con- Community Con- Total Asso-
Virus
Type
Cases tact Cases tact Cases ciated Cases
P NP P NP P NP P NP, Total
Type I 32 h h i 9 10 2 85 15 100
Type II 1 1 1
Type III 1 Y
1 1
All Types 33 5 U3 9 10 2 86 16 102
Total Cases 61 18 80 25 17 3 158 h6 20k
Reports of negative attempts at virus isolation are incomplete and are not 
included. Also not included is a report from Dr, John Fox (Tulane 
University) of the isolation of Type III virus from a fatal vaccinated case 
from which a previous isolation of Type I virus had also been made.
This table compiled from reports contributed by the following laboratories: 
Rocky Mountain Laboratory, NIH (Drs, Carl Larson and Karl Eklund)5 Tulane 
University School of Medicine (Drs# John Fox and Louis Potash)| Virus and 
Rickettsia Section, CDC (Drs, Morris Schaeffer and Robert Francis); 
University of Oregon School of Medicine (Dr, Arthur Frisch); Department 
of Bacteriology, University of Utah School of Medicine (Dr, Louis Gebhardb)* 
Virus and Rickettsial Laboratory, California Department of Public Health 
(Dr, Edwin Lennette); Yale University School of Medicine (Dr, Joseph 
Meinick); Laboratory of the Illinois Department of Public Health 
(Dr, Howard Shaughnessy); Department of Bacteriology and Immunology, 
Uhiversity of Minnesota (Dr, Jerome Syverton); and Virus Laboratory,
National Microbiological Institute (Dr, Alexis Shelokov),
Table 7
New York State Department of Health 
Poliongrelitis Rates by Vaccination Status^ 
in 6 to 10 Year Olds in Upstate New York-*8*1
(Preliminary Data, ]yky 21 to October 21, 1955) *
-ftVaccination Cases_______Rates per 100,000
Status Population P NP U T P NP T
Vaccinated in 195b - •
booster in 1955 23,370 0 8 0 8 m 3b, 2 3b, 2
no booster 7b,330 b 18 1 23 5,b 2b* 2 30,9
Vaccinated in 1955
one dose 18^,695 9 63 1 75 5*o 3b. 1 bl*3
two doses 169,17b _5 39 3 b7 3*0 23.1 27.8
Total Vaccinated bb8,569 18 128 5 153 b .o 28,5 3b.l
Total Uhvaccinated 282,000 59 111 8 178 20.9 39* b 63.1
v' Does not include 8 cases for which vaccination status is not known, 
? «» paralytic, NP»non-paralytic$ U - unspecified, T - total,
** Data compiled by Dr, William'Beadenkopf, Bureau of Epidemiology and 
Communicable Disease Control, and Dr, David Poskanzer, Epidemic 
Intelligence Service Offioer assigned to New York State*
Summary of Special Studies Reported from Eleven States and New York City 
(Preliminary Reports Received through November 1, 1955)
Table 8
Age
Group Period Studied ________Vaccinated _____ __________Unvaccinated
State Studied From To Population P NP U T Population P NP U T
California c to 8 6-15 10-15 395,000 13 1*7 60 1*31,000 1*3 1*5 88
Connecticut 5 to 5 1-1 10-22 106,120 6 38 1*1* 89,1*00 18 59 7 81*
Florida 5 to 9 l*-l5 10-21 ll*9,66it 2 23 25 221*,507 11 25 20 56
Georgia 6 to 11 l*-l6 10-23 17ii,200 6 6 r) 12 262,1*00 20 19 39
Illinois 6 to 9 1*-18 9-15 357,000 5 1*5 50 326,000 31* 80 111*
Maryland 5 to 9 U—12 10-8 112,000 1* 158,000 27
Minnesota 6 to 9 5-20 10-28 112,115 3 21 2i* 33,259 10 12 22
N. Y. City 6 to 7 6-1 10-21 166,000 9 13 22 87,000 19 32 51
N. Y. State 6 to 10 5-21 10-21 1*1*8,569 18 128 7 153 282,000 59 111 8 178
N. Carolina 5 to 9 1*-12 10-21 196,1466 1* 19 23 232,133 25 58 5 88
Oregon 7 to 9 5-22 8-23 1*7,852 1 2 3 1*6,188 7 1* 11
Washington 5 to 9 5-15 10-li* 69,123 1* 1 5 • 190,179 1*0 20 60
P - paralytic, NP - non-paralytic, U - unspecified, T - total. 
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Table 9
Summary of Special Studies Reported from Eleven States and New York City 
Poliomyelitis Attack Rates by Paralytic Status among Vaccinated and Unvaccinated Children
(Preliminary Reports Received through November 1, 1955)
State
Paralytic Rate 
per 100,000
Non-Paralytic Rate 
per 100.000
Total Rate 
per 100,000
Vaccinated Unvaccinated Vaccinated Unvaccinated Vaccinated Unvaccinated
California 3.3 10.0 11.9 10.1* 15.2 20.1*
Connecticut 5.7 20.1 35.8 66.0 1*1.5 9l*.0
Florida 1.3 U.9 15.1* 11.1 16.7 21*. 9
Georgia 3.1* 7.6 3.1* 7.2 6.9 11*. 9
Illinois 1.1* 10.1* 12.6 21*. 5 liuO 35.0
Maryland 3.6 17.1 — — — —
Minnesota 2.7 30,1 18.7 36.1 21,1* 66.1
New York City 5.U 21.8 7.8 36.8 13.3 58.6
New York State li.O 20.9 28.5 39.1* 3U.1 63.1
North Carolina 2.0 10.8 9.7 25.0 11.7 37.9
Oregon 2.1 15.2 1*.2 8.7 6.3 23.8
Washington 5.8 21.0 1.1* 10.5 7.2 31.5
See Table 8 for acknowledgements.
Table 10
AGE DISTRIBUTION ANALYSIS STUDY 
Age Distribution of Poliomyelitis in 1955 and 1952
1955 (33 States)__________ ______________1952 (21 States)
Age
Population
Estimates
Cases Rates-”- Population
Estimates
Cases Rates-*
P NP P NP P NP P NP
Under 1 2,8U8,000 lit8 61t 5.2 2.2 1,665,000 itOO 122 2it.O 7.3
1 2,778,000 29lt 9b 10.6 3.it l,62it,000 855 255 52.6 15.7
2 2,709,000 35it 196 13.1 7.2 1,555,000 908 365 58.it 23.5
3 2,637,000 306 282 11.6 10.7 1,565,000 919 it66 58.7 29.6
b 2,598,000 276 371 10.6 lit.3 i,55it,ooo 833 5ii6 53.6 35.1
0 -b 13,570,000 1378 1007 10.2 7.U 7,963,000 3915 I75it it9.2 22.0
5 2,it90,000 281 371 11.3 lit.9 1,68U,000 829 680 It9.2 b o .k
6 2,li97,000 231 375 9.3 15.0 l,2lit,000 737 558 60.7 it6.0
7 2,1|82,000 127 289 5.1 11.6 1,208,000 658 it87 5U.5 ito.3
8 2,67it,000 127 311 U.7 11.6 1,202,000 577 itlO U8.0 3U.1
9 1,936,000 1U5 236 7.5 12.2 1,270,000 509 itOl itO.l 31.6
5-9 12,079,000 911 1582 7.5 13.1 6,578,000 3310 2536 56.3 38.6
10 1,916,000 lltl 187 7. it 9.8 1,111,000 it26 362 38.3 32.6
11 1,926,000 121 217 6.3 11.3 I,0it7i000 391 287 37.3 27.U
12 2,036,000 litit 231 7.1 11.3 99it,000 339 2it7 3it.l 2U.8
13 1,788,000 125 192 7.0 10.7 998,000 315 218 31.6 21.8
lit 1,671,000 101 178 6.0 10.7 976,000 339 220 3it.7 22.5
10—li; 9,337,000 632 1005 6.8 10.8 5,126,000 1810 133it 35.3 26.0
o - lit 3it, 986,000 2921 359lt 8.3 10.3 19,667,000 9035 562it it5.9 28.6
15 plus 80,063,000 1687 19I18 2.1 2.it 5 o ,lt i5 ,o o o it 52 9 2521 9.0 5.0
Unknown 9 9 57 35
Total Il5,0it9,000 U6l7 5551 it.O it.8 70,082,000 13621 8180 19.it 11.7
*Per 100,000 population.
1955 data consist of preliminary reports through October lit from 33 states (see Figure 2) of cases with onsets 
July 3 or later, but do not include 632 cases with paralytic status unspecified. 1952 data consist of reports 
from 21 states (see Figure 2) of cases with onsets in the calendar year (195b- data have been substituted in 
Arizona, Indiana, Missouri and Tennessee), but do not include 3296 cases with paralytic status unspecified. 
Population estimates are for July 1, 1955, and were derived from data and methods provided by the Bureau of 
the Census.
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Figure 3
POLIOMYELITIS AGE-SPECIFIC ATTACK RATES 
IN 1955 (33 States) and 1952 (21 States)
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